South Korean Cryptocurrency Exchange Bithumb to List in the US via Reverse Merger

South Korean Cryptocurrency Exchange Bithumb to List in the US via Reverse Merger

South Korean cryptocurrency exchange Bithumb is planning to apply for listing in the US through a reverse merger.

Investment company Blockchain Industries, which already trades on the US OTC market, has signed a binding letter of intent agreement to conduct a reverse merger with BTHMB Holdings, the Singapore-based holding company that controls Bithumb.

Upon completion of the deal, the merged entity will be called Blockchain Exchange Alliance and has the potential to become the first cryptocurrency exchange to list in the US.

BTHMB Holdings has agreed to deposit $1 million into an escrow account as part of the agreement. The deal is subject to due diligence and agreement on terms and valuations.

Bradmer Pharmaceuticals

Bradmer Pharmaceuticals is a Canadian biopharmaceutical company that focuses on the development and commercialization of innovative cancer treatments. The company was founded in 2006 and is headquartered in Toronto, Canada.

History

In 2009, Bradmer Pharmaceuticals acquired the rights to develop and commercialize an anti-cancer drug called Nimotuzumab. The drug is designed to target cancer cells while leaving healthy cells intact. Nimotuzumab has been approved for use in several countries including Cuba, China, and India.

In 2011, Bradmer Pharmaceuticals was listed on the Toronto Stock Exchange Venture (TSX-V) through a reverse merger to facilitate listing in Canada.

Products

Bradmer Pharmaceuticals' main product is Nimotuzumab, which is currently in clinical trials for several different types of cancer including glioblastoma, pancreatic cancer, and head and neck cancer.

Mission

Bradmer Pharmaceuticals is committed to developing innovative cancer treatments that improve the lives of patients and provide hope to those living with cancer.